{"generic":"Butenafine Hydrochloride","drugs":["Butenafine Hydrochloride","Mentax"],"mono":{"0":{"id":"jsuis0","title":"Generic Names","mono":"Butenafine Hydrochloride"},"1":{"id":"jsuis1","title":"Dosing and Indications","sub":{"0":{"id":"jsuis1b4","title":"Adult Dosing","mono":"<ul><li><b>Pityriasis versicolor:<\/b> apply TOPICALLY to affected areas once daily for 2 wk<\/li><li><b>Tinea corporis:<\/b> apply TOPICALLY to affected areas once daily for 2 wk<\/li><li><b>Tinea cruris:<\/b> apply TOPICALLY to affected areas once daily for 2 wk<\/li><li><b>Tinea pedis, Interdigital:<\/b> apply TOPICALLY twice daily for 7 days or once daily for 4 wk<\/li><\/ul>"},"1":{"id":"jsuis1b5","title":"Pediatric Dosing","mono":"<ul><li>Safety and effectiveness not established in children under 12 yr of age<\/li><li><b>Pityriasis versicolor:<\/b> age 12-18 y, apply TOPICALLY to affected areas once daily for 2 wk<\/li><li><b>Tinea corporis:<\/b> age 12-18 y, apply TOPICALLY to affected areas once daily for 2 wk<\/li><li><b>Tinea cruris:<\/b> age 12-18 y, apply TOPICALLY to affected areas once daily for 2 wk<\/li><li><b>Tinea pedis, Interdigital:<\/b> age 12-18 y, apply TOPICALLY twice daily for 7 days or once daily for 4 wk<\/li><\/ul>"},"3":{"id":"jsuis1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Pityriasis versicolor<\/li><li>Tinea corporis<\/li><li>Tinea cruris<\/li><li>Tinea pedis, Interdigital<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Onychomycosis due to dermatophyte<\/li><li>Seborrheic dermatitis<\/li><\/ul>"}}},"3":{"id":"jsuis3","title":"Contraindications\/Warnings","sub":[{"id":"jsuis3b9","title":"Contraindications","mono":"hypersensitivity to butenafine products<br\/>"},{"id":"jsuis3b10","title":"Precautions","mono":"<ul><li>sensitivity to allyamine antifungals (ie, naftifine and terbinafine)<\/li><li>avoid contact with eyes, nose, mouth, and other mucous membranes<\/li><\/ul>"},{"id":"jsuis3b11","title":"Pregnancy Category","mono":"Butenafine: C (FDA)<br\/>"},{"id":"jsuis3b12","title":"Breast Feeding","mono":"Butenafine: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jsuis5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Contact dermatitis (less than 2%), Erythema (less than 2%), Itching (less than 2%), Skin irritation (less than 2%)<br\/>"},"6":{"id":"jsuis6","title":"Drug Name Info","sub":{"0":{"id":"jsuis6b17","title":"US Trade Names","mono":"Mentax<br\/>"},"2":{"id":"jsuis6b19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Benzylamine<\/li><\/ul>"},"3":{"id":"jsuis6b20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"jsuis6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jsuis7","title":"Mechanism Of Action","mono":"Butenafine hydrochloride is a synthetic antifungal agent that belongs to benzylamine class. It inhibits the synthesis of ergosterol, an essential component of fungal cell membranes, by blocking squalene epoxidation. It may be either fungicidal or fungistatic against most strains of Epidermophyton floccosum, Malassezia furfur and Trichophytons.<br\/>"},"8":{"id":"jsuis8","title":"Pharmacokinetics","sub":{"0":{"id":"jsuis8b23","title":"Absorption","mono":"<ul><li>Topical: time to peak concentration, 15 h +\/- 8 h (6-gram dose) and 6 h +\/- 6 h (20-gram dose)<\/li><li>Bioavailability: not quantitated<\/li><\/ul>"},"2":{"id":"jsuis8b25","title":"Metabolism","mono":"hydroxylation <br\/>"},"3":{"id":"jsuis8b26","title":"Excretion","mono":"Renal: as metabolites <br\/>"},"4":{"id":"jsuis8b27","title":"Elimination Half Life","mono":"greater than 150 h <br\/>"}}},"9":{"id":"jsuis9","title":"Administration","mono":"<b>Topical<\/b><br\/>apply sufficient product to cover affected areas and immediately surrounding skin <br\/>"},"10":{"id":"jsuis10","title":"Monitoring","mono":"<ul><li>resolution of symptoms (erythema, scaling, pruritus)<\/li><li>negative culture or microscopic exam in KOH<\/li><li>signs of increased irritation and sensitivity (redness, itching, burning, blistering, swelling, or oozing)<\/li><\/ul>"},"11":{"id":"jsuis11","title":"How Supplied","mono":"<ul><li><b>Lotrimin Ultra<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Mentax<\/b><br\/>Topical Cream: 1 %<br\/><\/li><\/ul>"},"12":{"id":"jsuis12","title":"Toxicology","sub":[{"id":"jsuis12b31","title":"Clinical Effects","mono":"<b>TERBINAFINE AND RELATED AGENTS<\/b><br\/>OVERDOSE: Limited data. Anticipate toxic effects similar to adverse events reported (predominantly dermatologic manifestations and gastrointestinal irritation). ADVERSE EVENTS: COMMON: Various dermal adverse reactions, including pustular and psoriasis-like eruptions, erythema multiforme, toxic epidermal necrolysis, and Stevens-Johnson syndrome have commonly occurred with oral terbinafine therapy. Cutaneous lupus erythematosus has also been reported. Nausea, vomiting, diarrhea, and abdominal pain can also develop following oral therapy. INFREQUENT: Ocular disturbances, taste impairment, leukopenia, renal impairment, and hepatotoxicity are infrequent occurrences following therapy. RARE: Hematologic effects including, neutropenia, agranulocytosis, and thrombocytopenia have occurred following chronic oral terbinafine therapy.<br\/>"},{"id":"jsuis12b32","title":"Treatment","mono":"<b>TERBINAFINE AND RELATED AGENTS <\/b><br\/><ul><li>Decontamination: Activated charcoal, after large ingestions. Most cases of toxicity reported have involved chronic ingestion of terbinafine.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Terbinafine serum levels are not clinically useful.  Monitor liver enzyme tests and CBC in symptomatic patients. Long-term administration of terbinafine may cause hepatotoxicity and\/or hematoxicity (ie, leukopenia, thrombocytopenia).<\/li><li>Hemodialysis: Due to the high degree of protein binding of terbinafine, hemodialysis is not anticipated to be effective.<\/li><\/ul>"},{"id":"jsuis12b33","title":"Range of Toxicity","mono":"<b>TERBINAFINE AND RELATED AGENTS<\/b><br\/>TOXICITY: Limited data. Doses up to 5 g (20 times the therapeutic daily adult dose) have been associated with mild toxicity (ie, nausea, vomiting, abdominal pain, dizziness, rash, frequent urination and headache). THERAPEUTIC DOSE: TINEA CAPITIS: ORAL GRANULES: ADULT: Weighing greater than 35 kg: 250 mg\/day for 6 weeks. PEDIATRIC: For children weighing between 25 and 35 kg: 187.5 mg\/day for 6 weeks and weighing less than 25 kg: 125 mg\/day for 6 weeks. <br\/>"}]},"13":{"id":"jsuis13","title":"Clinical Teaching","mono":"<ul><li>Patient should report if no symptomatic improvement after 3 to 4 weeks.<\/li><li>Instruct patient to skin should be clean and dry prior to application. Apply product to cover affected areas and immediately surrounding skin. Do not apply occlusive dressings.<\/li><li>Advise patient to avoid contact with eyes, nose, mouth, and other mucous membranes.<\/li><\/ul>"}}}